Primitive Neuroectodermal Tumors of the Central Nervous System Workup
- Author: Subrata Ghosh, MD, MBBS, MS; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS more...
Lab tests are not helpful in the diagnosis of primitive neuroectodermal tumors (PNET).
Diagnosis of these clinical entities is confirmed or excluded by lumbar puncture and CT scan and/or MRI. Presence of a mass lesion on an imaging study precludes lumbar puncture because of the risk of herniation.
Clinical diagnosis of these tumors is not possible. Radiologic features unique to each type of tumor may be helpful, but the only possible absolute confirmation is by pathologic examination of the surgical specimen.
MRI is the imaging technique of choice. The typical tumor is a heterogeneous mass with ill-defined margins arising from the vermis, which fills the fourth ventricle.
Typical findings include moderate to intense enhancement of the tumor, which is not homogenous (see image below).
Accompanying hydrocephalus is common (see image below), and associated cystic changes can occur (see image below).
The entire neuraxis should be imaged to detect spinal metastases, which may occur via subarachnoid dissemination.
In emergent situations, CT scan is preferred over MRI because of its easy accessibility. However, CT scan resolution is inferior to that of MRI. The mass is typically midline, relatively heterogeneous, and variably contrast enhancing. (See the image below.)
CT myelogram may be used to rule out spinal dissemination in cases in which MRI is contraindicated.
As compared to the normal cerebellum, these tumors on MR spectroscopy reveal a heterogeneous picture with decreased N- acetyl-aspartate (NAA) and creatine peaks and increased choline peaks.
The technique is still considered experimental.
See the list below:
Ventriculostomy is rarely done preoperatively because of the risk of upward herniation.
Preoperative lumbar puncture is avoided because of the risk of downward herniation.
See the list below:
Primitive cells are observed growing in sheets or cords of dense cellularity with increased mitotic index and increased nuclear-cytoplasmic ratio.
Formation of Homer-Wright rosettes (ie, neuroblastic rosettes consisting of tumor cell nuclei disposed in a circular fashion about tangled cytoplasmic processes) is typical but not always seen and is not essential for diagnosis. When present, it is frequently associated with marked nuclear pleomorphism and high mitotic activity.
Associated gross pathologic findings may include cystic changes, although the tumors are usually solid. They may vary from soft to firm in consistency. Geographic areas of necrosis, vascular proliferation, or calcification are less common, while hemorrhage is rare.
Immunohistochemical markers can confirm differentiation toward astrocytic or neuronal lineage.
Unusual variants include those with melanin deposition, rhabdomyoblastic differentiation, or desmoplastic features, among others.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug. 114 (2):97-109. [Medline].
Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009 Jul. 6(3):570-86. [Medline].
Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993 Jul. 3(3):255-68. [Medline].
Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012 Nov. 19 (11):1541-4. [Medline].
Huppmann AR, Orenstein JM, Jones RV. Cerebellar medulloblastoma in the elderly. Ann Diagn Pathol. 2009 Feb. 13(1):55-9. [Medline].
Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer. 2012 Mar 1. 118 (5):1313-22. [Medline].
Gulino A, Arcella A, Giangaspero F. Pathological and molecular heterogeneity of medulloblastoma. Current Opinions in Oncology. November 2008. 20(6):668-75.
Guessous F, Li Y, Abounader R. Signalling pathways in Medulloblastoma. Journal of Cell Physiology. December 2008. 217(3):577-583.
Li KK, Lau KM, Ng HK. Signaling pathway and molecular subgroups of medulloblastoma. Int J Clin Exp Pathol. June 2013. 6 (7):2111-22. [Medline].
Crawford JR, Rood BR, Rossi CT, Vezina G. Medulloblastoma associated with novel PTCH mutation as primary manifestation of Gorlin syndrome. Neurology. 2009 May 5. 72(18):1618. [Medline].
Allen JC, Donahue B, DaRosso R, Nirenberg A. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys. 1996 Dec 1. 36(5):1155-61. [Medline].
Ajeawung NF, Wang HY, Kamnasaran D. Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas. Cancer Lett. April 2013. 330 (2):130-40. [Medline].
Min HS, Lee JY, Kim SK, Park SH. Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis. Transl Oncol. June 2013. 6 (3):265-72. [Medline].
Albright AL, Pollack IF, Adelson PD. Principles and Practice of Pediatric Neurosurgery. 1st ed. New York: Thieme. 1999: 591-608.
Goldwein JW, Radcliffe J, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys. 1996 Mar 1. 34(4):899-904. [Medline].
Graham DI, Lantos PL. Greenfield's Neuropathology. 6th ed. New York: Oxford University Press; 1997. Vol 2: 698-710.
Kay A, et al. Brain tumors. First ed. New York: Churchill Livingstone; 1997. 561-574.
Kleihues P, Cavanee WK. Pathology and genetics of tumours of the nervous system. Lyon, France: International Agency for Research on Cancer (IARC); 1997. 49-55.
Kun LE. Brain tumors. Challenges and directions. Pediatr Clin North Am. 1997 Aug. 44(4):907-17. [Medline].
Prados MD, Wara W, Edwards MS, et al. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy. Pediatr Neurosurg. 1996 Oct. 25(4):174-81. [Medline].
Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol. 2004 Oct. 31(5):666-75. [Medline].
Russell DS, et al. Pathology of Tumors of the Nervous System. 4th ed. Baltimore: Williams & Wilkins; 1977. 203-26.